EUVIMEDEUVIMED entdecken
Crossref

Pivmecillinam (Pivya) for Uncomplicated UTI

The Medical Letter on Drugs and Therapeutics · 13.04.2026 · 68 (1752) · 57-59

DOI: 10.58347/tml.2026.1752a ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 13.04.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved pivmecillinam (Pivya – Utility Therapeutics), an oral penicillin-class antibacterial drug, for treatment of uncomplicated urinary tract infections (uUTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis, or Staphylococcus saprophyticus in adult females. Pivmecillinam was approved by the FDA in 2024 but only recently became available in the US. It has been used in Europe for over 40 years.

Schlagwörter

Stichwörter der Autor:innen

BactrimBlujepaMacrobidOrlynvahPivyaadverse effectsantibacterialscephalexindosagedrug interactionsefficacyetzadroxilfosfomycingepotidacinibuprofen

Zitieren

APA

(2026). Pivmecillinam (Pivya) for Uncomplicated UTI. The Medical Letter on Drugs and Therapeutics, 68(1752), 57-59. https://doi.org/10.58347/tml.2026.1752a

Vancouver

Pivmecillinam (Pivya) for Uncomplicated UTI. The Medical Letter on Drugs and Therapeutics. 2026;68(1752):57-59. doi:10.58347/tml.2026.1752a

BibTeX
@article{euvimed2026,
  title = {Pivmecillinam (Pivya) for Uncomplicated UTI},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1752},
  pages = {57--59},
  doi = {10.58347/tml.2026.1752a}
}
Kostenlos starten →